Base de dados : MEDLINE_1966-1996 Pesquisa : C14.907.489 [Categoria DeCS] Referências encontradas : 90986 [refinar] Mostrando: 1 .. 10   no formato [Longo]

página 1 de 9099

ir para página

1 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 17217011 Autor: Moneim IA Endereço: Occupational Health Department, High Institute of Public Health, Alexandria University. Título: Audiometric pattern in a group of workers with one ear conductive deafness exposed to continuous noise. Fonte: J Egypt Public Health Assoc; 71(3-4):243-56, 1996. ISSN: 0013-2446 País de publicação: Egypt Idioma: eng Resumo: BACKGROUND: It is common to find workers in developing countries having residual ear problems from childhood affections. When exposed to continuous noise in industry, they might exhibit different patterns of audiometric findings. The aim of this study was to examine the good ear in a group of workers exposed to continuous noise in textile industry with a perforated drum in the other ear from childhood otitis media. METHODS: a 1:2 case control design involving a group of 36 cases and 2 matched groups, same age and duration of exposure was performed. A relevant questionnaire was used and each worker was subjected to an audiometric test. RESULTS: significantly worse hearing threshold levels at the 250 Hz and the 4 kHz frequencies were obtained for the good ears of cases compared to controls. Subjective complaints were also commoner. A different pattern of hearing loss was found adding to the auditory risk of the involved workers. Tipo de publicação: JOURNAL ARTICLE

2 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 10457807 Autor: Adegunloye BJ; Sofola OA Endereço: Department of Physiology, College of Medicine, University of Lagos, Nigeria. Título: The effects of high dietary calcium on salt-induced hypertension in rats. Fonte: Afr J Med Med Sci; 25(3):285-91, 1996 Sep. ISSN: 0309-3913 País de publicação: NIGERIA Idioma: eng Resumo: The effects of dietary salt-loading and concurrent administration of dietary calcium on water and electrolyte excretion in Sprague-Dawley rats have been studied. The total salt consumed by salt-loaded rats was significantly higher than that of control rats (P < 0.05). The total salt consumed by salt-loaded calcium fed rats was also higher (P < 0.05) than that of control rats but it was slightly lower (P < 0.05) than the consumption by the salt-loaded. Rats fed only high calcium diet had the least salt consumption. The total water intake was also highest (P < 0.05) in the salt-loaded rats when compared with either control rats, salt-loaded-calcium-fed rats or calcium-fed rats. Urinary water excretion was highest (P < 0.05) in salt-loaded-calcium-fed rats followed by salt-loaded rats and calcium-fed rats while the control rats had the least. Similarly, the sodium excretion was highest in salt-loaded-calcium-fed rats followed by salt-loaded rats and calcium-fed rats and control rats respectively. Potassium excretion was highest in salt-loaded-calcium-fed rats followed by salt-loaded rats and calcium-fed rats while the control rats had the least excretion of potassium. Serum sodium concentrations were identical in all the groups although in salt-loaded rats and salt-loaded-calcium-fed rats the values were slightly higher than those of controls. However, serum potassium concentration was lowest in salt-loaded rats and calcium-fed rats while the values for salt-loaded-calcium-fed rats was not significantly different from that of control. The results of this study suggest that increase in dietary calcium intake reduces the increase in blood pressure resulting from salt-loading and this is accompanied by an increase in water and sodium excretion. Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T Nome de substância: 0 (Calcium, Dietary); 0 (Sodium Chloride, Dietary); 7440-09-7 (Potassium); 7440-23-5 (Sodium)

3 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 10457806 Autor: Balogun MO; Dunn FG Endereço: Department of Medicine, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. Título: Left ventricular hypertrophy as a risk factor in hypertension. Fonte: Afr J Med Med Sci; 25(3):277-83, 1996 Sep. ISSN: 0309-3913 País de publicação: NIGERIA Idioma: eng Resumo: Hypertension is established as one of the major risk factors for congestive heart failure, renal failure, cerebrovascular accident and coronary artery disease. Left ventricular hypertrophy (LVH) is an adaptive response to the increased afterload in hypertension, and therefore serves to normalize wall stress. However, LVH has been established as an independent risk factor for adverse cardiovascular events and death in hypertension. For this reason, considerable attention has been directed towards a better understanding of LVH as a risk factor. As recognition of the risk associated with LVH has grown, investigators have increasingly focused attention on improving methods for the detection of LVH, assessing its effects on cardiac function, defining its relationship with myocardial ischaemia and sudden death, evaluating the role of antihypertensive treatment in the regression of LVH and assessing whether such regression is beneficial in the long term. Tipo de publicação: JOURNAL ARTICLE; REVIEW

4 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 10457792 Autor: Sowunmi A; Walker O; Salako LA Endereço: Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria. Título: Amlodipine as monotherapy in hypertensive Africans: clinical efficacy and safety studies. Fonte: Afr J Med Med Sci; 25(3):213-6, 1996 Sep. ISSN: 0309-3913 País de publicação: NIGERIA Idioma: eng Resumo: Amlodipine as a monotherapy was evaluated in 20 patients with mild, moderate, and severe hypertension over a 10 week period. After a washout period of 4 weeks, Amlodipine was administered at a dose of 5 mg once daily for 2 weeks and increased to 10 mg once daily if diastolic blood pressure did not fall to below 90 mmHg. At the end of the trial, diastolic blood pressure was reduced to below 90 mmHg in all but four patients. However, these four patients had greater than 20 mmHg reduction in diastolic blood pressure. There was a slight, but insignificant increase in heart rate. Dizziness and weakness occurred in one patient, otherwise, the drug was well tolerated. Laboratory tests, including plasma lipids done at the start and end of the trial, remained unchanged. Tipo de publicação: CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE Nome de substância: 0 (Antihypertensive Agents); 0 (Calcium Channel Blockers); 88150-42-9 (Amlodipine)

5 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia PubMed Central Texto completo

PMID: 10323116 Autor: Sunada K; Nakamura K; Yamashiro M; Sumitomo M; Furuya H Endereço: Department of Anesthesiology, Nippon Dental University, School of Dentistry at Tokyo, Japan. Título: Clinically safe dosage of felypressin for patients with essential hypertension. Fonte: Anesth Prog; 43(4):108-15, 1996. ISSN: 0003-3006 País de publicação: UNITED STATES Idioma: eng Resumo: Hemodynamic changes were evaluated in patients with essential hypertension when felypressin of various concentrations was administered. The parameters studied were systolic pressure, diastolic pressure, heart rate, left ventricular systolic phase, and endocardial viability ratio. Results showed that blood pressure tended to increase, and the value of 1/pre-ejection period2 (PEP2) tended to decrease, upon administration of 3 ml of 2% propitocaine containing 0.06 international units/ml (IU/ml) of felypressin. Significant increase of blood pressure and decrease in 1/PEP2 was noted upon administration of 3 ml of anesthetic solution containing 0.13 IU/ml of felypressin. No ischemic change of the myocardium was detected even with the highest felypressin concentration (3 ml of 2% propitocaine containing 0.25 IU/ml of felypressin). These results suggest that the clinically safe dosage of felypressin for patients with essential hypertension is approximately 0.18 IU. This amount is equivalent to 6 ml of 3% propitocaine with 0.03 IU/ml of felypressin, which is a commercially available local anesthetic for dental use. It seems that the decrease in 1/PEP2 that occurred during blood pressure increase was due to the increase in afterload caused by contraction of the arterioles. Although in the present study no ischemic change was noted, special care should be taken to prevent myocardial ischemia in patients with severe hypertension. Tipo de publicação: CLINICAL TRIAL; JOURNAL ARTICLE Nome de substância: 0 (Vasoconstrictor Agents); 56-59-7 (Felypressin)

6 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 9863143 Autor: Hu WY; Chen DG; Chen SC; Jin XQ; Wang HJ Endereço: Hypertension Division, First Affiliated Hospital, Fujian Medical College, Fuzhou, China. Título: Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats. Fonte: Zhongguo Yao Li Xue Bao; 17(6):507-12, 1996 Nov. ISSN: 0253-9756 País de publicação: CHINA Idioma: eng Resumo: AIM: To study the effect of captopril treatment and its withdrawal on the circulating and tissue peptidyl-dipeptidase A, angiotensinogen (AGT), and angiotensin II (A II), in relation to left ventricular hypertrophy (LVH) and systolic blood pressure (SBP). METHODS: SHR male rats were given captopril 100 mg.kg-1.d-1 [SHRcap, number (n) = 43] orally in mixture with milk powder as vehicle from intrautero period of 16 wk of age. Rats were killed at 16 (n = 19) and 40 (n = 24) wk of age, respectively. Male, age-matched untreated SHR and WKY rats served as controls. SBP, left ventricular mass/body weight (LVM/BW) ratio, left ventricular (LV) myocardium and plasma A II concentration, aortic and serum peptidyl-dipeptidase A activity, AGT mRNA level in kidney and liver, renal renin mRNA level were determined. RESULTS: Captopril treatment decreased SBP and reduced LVM/BW at 16 and 40 wk of age, and persistently inhibited LV myocardium A II, aortic peptidyl-dipeptidase A activity, and AGT gene expression in kidney even after the treatment was removed. Nevertheless, no changes were found in plasma A II concentration, serum peptidyl-dipeptidase A activity, and AGT mRNA level in liver by captopril therapy. Renal renin mRNA level was low in SHR and WKY rats, but it was increased by captopril treatment. Tissue renin-angiotensin system (RAS) such as AGT mRNA in kidney, aortic peptidyl-dipeptidase A activity, and LV myocardium A II, rather than circulating RAS (AGT mRNA in liver, renin mRNA in kidney, serum peptidyl-dipeptidase A activity and plasma A II), were persistently inhibited by early captopril treatment, even after the withdrawal of the treatment. CONCLUSION: The long-term inhibition of tissue RAS is one of the mechanisms of the persistent hypotensive effect of captopril treatment. Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T Nome de substância: 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (RNA, Messenger); 11002-13-4 (Angiotensinogen); 11128-99-7 (Angiotensin II); 62571-86-2 (Captopril); EC 3.4.15.1 (Peptidyl-Dipeptidase A)

7 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 9827096 Autor: Cisse CT; Fall PA; Moreira IV; Terolbe I; Diallo D; Diouf A; Ndiaye PA; Moreau JC; Diadhiou F Endereço: Clinique Gynécologique et Obstétricale, CHU A. Le Dantec, Dakar. Título: [Cesarean section in a developing country. Profile and perspectives apropos of 21,743 deliveries between 1992 and 1995] Título: La césarienne dans un pays en développement. Bilan et perspectives à propos de 21743 accouchements entre 1992 et 1995.. Fonte: Dakar Med; 41(1):63-7, 1996. ISSN: 0049-1101 País de publicação: SENEGAL Idioma: fre Resumo: In three years and six month 21,743 delivered at the Maternity of Dakar University Hospital. Among them there were 2650 cesarean section. The cesarean rate is 16.93% of living birth. The principal indication was foeto-pelvic disproportion (32.5%) especially pelvic problem (27%). There was post operative mortality (1%) (especially hypertension) and morbidity (6%) (especially infection). Neonatal prognosis was also poor with a 10% early neonatal mortality. These findings show the important insufficiency and reflect major problems facing obstetric in Black Africa. Tipo de publicação: ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW

8 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 9816119 Autor: Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE Endereço: Departments of Obstetrics and Gynecology, Surgery, and Pharmacology and Comprehensive Cancer Center Clinical Research Office, Yale University School of Medicine, New Haven, Connecticut 06520-8063, USA. Título: Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Fonte: Clin Cancer Res; 2(10):1699-704, 1996 Oct. ISSN: 1078-0432 País de publicação: UNITED STATES Idioma: eng Resumo: Our objective was to determine the maximum tolerated dose of cyclosporin A (CsA) delivered as a loading dose (LD) and continuous i.v. infusion (CI) in combination with carboplatin in patients with refractory gynecologic cancers. Twenty-nine heavily pretreated patients (25 ovarian epithelial, 2 cervical, and 2 endometrial carcinomas) received 113 cycles of CsA and carboplatin from September 1989 to September 1991. Twenty-four of these 29 carcinomas were strictly defined to be platinum resistant. CsA was administered as a LD escalated from 6 to 10 mg/kg followed by a 24-h CI from 2.5 to 14.5 mg/kg/day. Carboplatin was targeted to an area under the time versus concentration curve (AUC) of 6 mg/ml x min and was not dose escalated. Whole-blood CsA concentrations (fluorescence polarization immunoassay) at the maximum tolerated dose (10 mg/kg LD, 14.5 mg/kg/day CI) ranged from 2.4 to 3.0 microgram/ml over 12 h. Estimated median carboplatin AUC, based on calculated carboplatin clearance, was 7.9 mg/ml x min. The dose-limiting toxicity of the combination of CsA and carboplatin was grade 4 thrombocytopenia. Grade 3 or 4 thrombocytopenia occurred in 35% of the patients, which could be explained by the effects of carboplatin (AUC of 6 mg/ml x min) alone. Overall, neutropenia occurred in 24% of the patients and anemia in 17% of the patients. Grade 3 or 4 nausea or vomiting was noted in 10 and 14% of the patients, respectively. Grade 3 hypertension during CsA administration occurred in 14% of the patients. No grade 3 or 4 nephrotoxicity was seen in this trial. Three objective responses were noted: one complete response (11 months) and one partial response (5 months), both in potentially platinum-sensitive patients with platinum-free intervals of only 9 months each. One platinum-resistant patient had a partial response for 21 months. Five additional patients experienced >75% reduction of CA-125 or a return to a normal CA-125 titer. We concluded that whole-blood CsA concentrations of >3.0 microgram/ml (as seen when CsA is used as a modulator of multidrug resistance) were not achievable in this combination with carboplatin in this population of heavily pretreated gynecologic cancer patients. However, because CsA is used in this trial as a chemosensitizer in platinum-sensitive tumors and as a chemomodulator of platinum resistance, we targeted a CsA concentration of >1.0 microgram/ml, which was achieved. The CsA dose recommended for a Phase II trial of this combination is 10 mg/kg LD and 11.6 mg/kg/day CI, which results in blood CsA concentrations ranging from 1.2 to 1.3 microgram/ml over 12 h. Responses in this population of refractory gynecologic cancer patients are unusual, and these encouraging results form the basis for a Phase II trial of this combination. Tipo de publicação: CLINICAL TRIAL; CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T Nome de substância: 0 (Antineoplastic Agents); 0 (Immunosuppressive Agents); 41575-94-4 (Carboplatin); 59865-13-3 (Cyclosporine)

9 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 9816118 Autor: Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT Endereço: Department of Obstetrics and Gynecology, Comprehensive Cancer Center Clinical Research Office, Yale University School of Medicine, New Haven, Connecticut 06520-8063, USA. Título: Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Fonte: Clin Cancer Res; 2(10):1693-7, 1996 Oct. ISSN: 1078-0432 País de publicação: UNITED STATES Idioma: eng Resumo: Our objective was to assess the activity of cyclosporin A (CsA) used as a chemomodulator of carboplatin in refractory ovarian and fallopian tube cancer patients. Fifty-one patients (47 epithelial ovarian, 1 ovarian mixed mesodermal tumor, and 3 fallopian tube carcinomas) were enrolled in a prospective Phase II trial of CsA and carboplatin. CsA was infused as a loading dose of 10 mg/kg over 5 h, followed by carboplatin infused over 30 min at an AUC of 6 mg/ml x min, then a 24-h continuous infusion of 11.6 mg/kg CsA. The patients received this protocol as second- to sixth-line therapy and had received between 1 and 3 prior platinum-based regimens. Eight patients received more than six cycles every 28 days, 34 patients received three to six cycles; and 9 patients received only one or two cycles. Thirty-eight patients were evaluable for objective response, and in an additional nine patients, CA-125 was the only marker of response. Four patients had no marker of disease. Of evaluable patients, 74% were platinum resistant. There were nine objective responses (one complete and eight partial responses) for an overall response rate in evaluable patients of 24%, with a median duration of response of 7 months (range, 3-38+ months). No responses were seen in patients who had received only one or two cycles of therapy. Among the strictly defined platinum-resistant patients, there was an overall 14% response rate, including one partial response seen after five prior regimens of chemotherapy including paclitaxel, and one ongoing complete response for 38+ months. Among the rest of the patients (those who were potentially platinum sensitive), there was an overall 50+ response rate; four of five responses were seen in patients with a platinum-free interval of <24 months, with only one response seen in a patient with a platinum-free interval of >24 months. Of evaluable patients, 34% had stable disease for a duration of 3-19 months. The most common grade 3 or 4 toxicity, thrombocytopenia, was seen in 22% of the patients. Hypertension, which responded to medications, was seen in 18% of the patients during the CsA infusion. We concluded that this CsA/carboplatin regimen is active in potentially platinum-sensitive patients and compares well with the expected response rate of 30% in patients with a platinum-free interval <24 months who are retreated with platinum. Moreover, this regimen had modest but real activity in platinum-resistant patients. Tipo de publicação: CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE Nome de substância: 0 (Antineoplastic Agents); 0 (Immunosuppressive Agents); 41575-94-4 (Carboplatin); 59865-13-3 (Cyclosporine)

10 / 90986

MEDLINE_1966-1996

seleciona para imprimir Fotocópia

PMID: 9812744 Autor: Wang J; Zhang L; Qi JH; Zhang PJ; Wei PJ; Gu PK; Jin ZJ Endereço: Department of Pharmacology, Shanghai Second Medical University, China. Título: Effects of captopril and enalaprilat on intracellular Ca2+ content in isolated cardiomyocytes from rats. Fonte: Zhongguo Yao Li Xue Bao; 17(3):233-5, 1996 May. ISSN: 0253-9756 País de publicação: CHINA Idioma: eng Resumo: AIM: To study the effects of ACEI captopril (Cap) and enalaprilat (Ena) on intracellular Ca2+ concentration ([Ca2+]i) in cardiac myocytes isolated from SHR and WKY rats. METHODS: Using fluorescent probe Fura 2-AM combined with computer image processing technique to measure [Ca2+]i. RESULTS: Resting [Ca2+]i was higher in SHR cardiac myocytes (174 +/- 5 nmol.L-1) than that in WKY rat myocytes (148 +/- 15 nmol.L-1, P < 0.01). Cap and Ena decreased the resting [Ca2+]i in SHR myocytes (161 +/- 11 and 166 +/- 7 nmol.L-1, respectively, P < 0.05) but not in WKY rat myocytes (P > 0.05). Both drugs inhibited [Ca2+]i increment induced by KCI, NE, or Ang II in SHR and WKY rat myocytes except on KCI-induced [Ca2+]i increment in WKY rat myocytes (P > 0.05). CONCLUSION: Cap and Ena had direct effects on pathological voltage-operated calcium channel in cardiac myocytes. Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T Nome de substância: 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Calcium Channels); 62571-86-2 (Captopril); 7440-70-2 (Calcium); 84680-54-6 (Enalaprilat)

---

página 1 de 9099

ir para página

Refinar a pesquisa

Base de dados : MEDLINE_1997-2009MEDLINE_1966-1996

Formulário avançado

Pesquisar por : Formulário livre    Formulário básico

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloIdiomaPaís de publicaçãoNome de substânciaSímbolo de geneNome de pessoa como assuntoRevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAtualização por classeAno de publicaçãoCategoria DeCSTexto completo SciELOSubSetsPais de AfiliaçãoAfiliação
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloIdiomaPaís de publicaçãoNome de substânciaSímbolo de geneNome de pessoa como assuntoRevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAtualização por classeAno de publicaçãoCategoria DeCSTexto completo SciELOSubSetsPais de AfiliaçãoAfiliação
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloIdiomaPaís de publicaçãoNome de substânciaSímbolo de geneNome de pessoa como assuntoRevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAtualização por classeAno de publicaçãoCategoria DeCSTexto completo SciELOSubSetsPais de AfiliaçãoAfiliação

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde